<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Revenue Bridge & Margin Analysis - Indegene</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 20px; line-height: 1.6; background: #f8f9fa; }
        .header { text-align: center; background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%); color: white; padding: 30px; border-radius: 12px; margin-bottom: 30px; }
        table { width: 100%; border-collapse: collapse; margin: 20px 0; box-shadow: 0 4px 12px rgba(0,0,0,0.1); background: white; border-radius: 8px; overflow: hidden; }
        th, td { border: 1px solid #e2e8f0; padding: 12px 15px; text-align: center; }
        th { background: linear-gradient(135deg, #1e40af 0%, #3b82f6 100%); color: white; font-weight: 600; }
        .highlight { background-color: #dbeafe; font-weight: 600; }
        .metric { font-weight: 700; color: #1e3a8a; }
        .organic { background-color: #dbeafe; }
        .inorganic { background-color: #fce7f3; }
        h2 { color: #1e3a8a; margin-top: 30px; margin-bottom: 15px; font-size: 1.3em; border-bottom: 3px solid #3b82f6; padding-bottom: 8px; }
        .waterfall { background: #f0f4f8; padding: 15px; border-radius: 8px; margin: 15px 0; }
        footer { text-align: center; margin-top: 40px; padding: 20px; background: white; border-radius: 8px; box-shadow: 0 2px 8px rgba(0,0,0,0.1); font-size: 0.85em; }
    </style>
</head>
<body>
    <div class="header">
        <h1>Revenue Bridge & Margin Analysis</h1>
        <p>FY25 Actual to FY30E Growth Drivers</p>
    </div>

    <h2>Revenue Bridge: FY25 to FY30E</h2>
    <table>
        <tr>
            <th>Component</th>
            <th>FY25</th>
            <th>Organic<br>Growth</th>
            <th>BioPharm<br>Addition</th>
            <th>FY30E</th>
            <th>CAGR</th>
        </tr>
        <tr class="highlight">
            <td><strong>Revenue (₹ Bn)</strong></td>
            <td class="metric">28.4</td>
            <td class="organic">+26.8</td>
            <td class="inorganic">+5.0</td>
            <td class="metric">60.2</td>
            <td class="metric">16.3%</td>
        </tr>
        <tr>
            <td>Organic CAGR</td>
            <td colspan="2" class="metric">15.2%</td>
            <td colspan="2">Indegene core business</td>
            <td>-</td>
        </tr>
        <tr>
            <td>M&A Addition</td>
            <td>-</td>
            <td colspan="2" class="inorganic">5.0 (BioPharm annualized)</td>
            <td>8.3% of FY30E</td>
            <td>-</td>
        </tr>
    </table>

    <h2>Revenue Mix Evolution (% of Total)</h2>
    <table>
        <tr>
            <th>Segment</th>
            <th>FY25</th>
            <th>FY26E</th>
            <th>FY27E</th>
            <th>FY28E</th>
            <th>FY30E</th>
            <th>CAGR</th>
        </tr>
        <tr>
            <td>ECS (Enterprise Commercial)</td>
            <td>56%</td>
            <td>58%</td>
            <td>59%</td>
            <td>60%</td>
            <td>62%</td>
            <td class="metric">18.5%</td>
        </tr>
        <tr class="highlight">
            <td>EMS (Enterprise Medical)</td>
            <td>28%</td>
            <td>28%</td>
            <td>28%</td>
            <td>27%</td>
            <td>26%</td>
            <td>12.8%</td>
        </tr>
        <tr>
            <td>Brand Activation</td>
            <td>12%</td>
            <td>10%</td>
            <td>10%</td>
            <td>10%</td>
            <td>9%</td>
            <td>-5.2%</td>
        </tr>
        <tr>
            <td>Others</td>
            <td>4%</td>
            <td>4%</td>
            <td>3%</td>
            <td>3%</td>
            <td>3%</td>
            <td>-4.5%</td>
        </tr>
    </table>

    <h2>EBITDA Margin Progression</h2>
    <table>
        <tr>
            <th>Year</th>
            <th>Revenue<br>₹ Bn</th>
            <th>EBITDA<br>₹ Bn</th>
            <th>Margin</th>
            <th>YoY<br>Change</th>
            <th>Driver</th>
        </tr>
        <tr class="highlight">
            <td><strong>FY25 Actual</strong></td>
            <td>28.4</td>
            <td class="metric">5.6</td>
            <td class="metric">19.8%</td>
            <td>+50bps</td>
            <td>Operating leverage</td>
        </tr>
        <tr>
            <td>FY26E</td>
            <td>34.0</td>
            <td>6.6</td>
            <td>19.5%</td>
            <td>-30bps</td>
            <td>M&A integration costs</td>
        </tr>
        <tr>
            <td>FY27E</td>
            <td>39.1</td>
            <td>7.8</td>
            <td>20.0%</td>
            <td>+50bps</td>
            <td>Synergy realization</td>
        </tr>
        <tr>
            <td>FY28E</td>
            <td>44.9</td>
            <td>9.2</td>
            <td>20.5%</td>
            <td>+50bps</td>
            <td>Operational scale</td>
        </tr>
        <tr class="highlight">
            <td><strong>FY30E</strong></td>
            <td>60.2</td>
            <td class="metric">13.7</td>
            <td class="metric">22.8%</td>
            <td>+230bps</td>
            <td>Full synergies + Tectonic</td>
        </tr>
    </table>

    <div class="waterfall">
        <h3>Margin Bridge: FY25 (19.8%) → FY30E (22.8%)</h3>
        <table style="margin-top: 15px;">
            <tr>
                <th>Item</th>
                <th>Impact<br>(bps)</th>
                <th>Rationale</th>
            </tr>
            <tr>
                <td>Operating leverage</td>
                <td class="metric">+80</td>
                <td>16% revenue growth on 10% cost growth</td>
            </tr>
            <tr>
                <td>Tectonic mix shift</td>
                <td class="metric">+40</td>
                <td>Higher margin transformational deals</td>
            </tr>
            <tr>
                <td>BioPharm synergies</td>
                <td class="metric">+60</td>
                <td>Scale + overhead absorption</td>
            </tr>
            <tr>
                <td>Talent optimization</td>
                <td class="metric">+30</td>
                <td>Offshore/onshore mix improvement</td>
            </tr>
            <tr>
                <td>M&A integration (drag)</td>
                <td class="metric">-40</td>
                <td>FY26-27 one-time costs</td>
            </tr>
            <tr class="highlight">
                <td><strong>Net Margin Expansion</strong></td>
                <td class="metric"><strong>+230</strong></td>
                <td><strong>Cumulative impact</strong></td>
            </tr>
        </table>
    </div>

    <h2>Historical Margin Trend (FY22-FY25)</h2>
    <table>
        <tr>
            <th>Year</th>
            <th>Revenue<br>₹ Bn</th>
            <th>EBITDA<br>₹ Bn</th>
            <th>Margin</th>
            <th>PAT<br>₹ Bn</th>
            <th>PAT Margin</th>
        </tr>
        <tr>
            <td>FY22</td>
            <td>20.8</td>
            <td>3.8</td>
            <td>18.3%</td>
            <td>2.2</td>
            <td>10.6%</td>
        </tr>
        <tr>
            <td>FY23</td>
            <td>23.1</td>
            <td>4.4</td>
            <td>19.0%</td>
            <td>2.7</td>
            <td>11.7%</td>
        </tr>
        <tr>
            <td>FY24</td>
            <td>25.9</td>
            <td>5.4</td>
            <td>20.8%</td>
            <td>3.4</td>
            <td>13.1%</td>
        </tr>
        <tr class="highlight">
            <td><strong>FY25</strong></td>
            <td>28.4</td>
            <td class="metric">5.6</td>
            <td class="metric">19.8%</td>
            <td class="metric">4.1</td>
            <td class="metric">14.3%</td>
        </tr>
        <tr>
            <td>5-Yr CAGR</td>
            <td class="metric">8.1%</td>
            <td class="metric">10.3%</td>
            <td>+150bps</td>
            <td class="metric">17.0%</td>
            <td>+370bps</td>
        </tr>
    </table>

    <footer>
        <p>Analysis based on Indegene FY25 Annual Report, H1 FY26 results, and BioPharm acquisition details. As of Dec 27, 2025.</p>
    </footer>
</body>
</html>